Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)

Next Previous
Trial Profile

A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2019

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms CLARITY EXT; CLARITY EXTENSION
  • Sponsors EMD Serono

    • Most Recent Events

    • 01 Jul 2019 Results assessing impact of non randomized droup out on treatment switching adjustment using CLARITY and CLARITY Extension trial published in the Value in Health
    • 28 May 2019 According to an EMD Serono media release, data from this trial will be presented at Consortium of Multiple Sclerosis Centers (CMSC) 2019 Annual Meeting.
    • 30 Apr 2019 According to an EMD Serono media release, integrated analysis of pooled long-term safety data of cladribine tablets in patients with MS collated from the CLARITY, CLARITY Extension, ORACLE-MS studies and the PREMIERE registry will be presented at the AAN Annual Meeting 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top